- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
Patent holdings for IPC class C07D 211/14
Total number of patents in this class: 389
10-year publication summary
21
|
26
|
27
|
22
|
26
|
30
|
24
|
28
|
25
|
16
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bristol-myers Squibb Company | 4898 |
7 |
Incyte Corporation | 1024 |
7 |
University of Pittsburgh - Of the Commonwealth System of Higher Education | 3151 |
7 |
Nocion Therapeutics, Inc. | 42 |
7 |
Incyte Holdings Corporation | 660 |
6 |
Janssen Pharmaceutica N.V. | 3392 |
5 |
Centre National de La Recherche Scientifique | 10418 |
5 |
Massachusetts Institute of Technology | 10057 |
5 |
Cassava Science, Inc. | 13 |
5 |
BASF SE | 20933 |
4 |
Immunomet Therapeutics Inc. | 31 |
4 |
Modernatx, Inc. | 1263 |
4 |
Toyama Chemical Co., Ltd. | 102 |
4 |
Anji Pharmaceuticals Inc. | 34 |
4 |
Etherna Immunotherapies NV | 58 |
4 |
Libra Therapeutics, Inc. | 10 |
4 |
Boehringer Ingelheim International GmbH | 4650 |
3 |
Chevron U.S.A. Inc. | 3955 |
3 |
JSR Corporation | 2517 |
3 |
Chong Kun Dang Pharmaceutical Corp. | 233 |
3 |
Other owners | 295 |